Keywords: Gilead Sciences, Truvada, NDA, TMC278, Tibote, Johnson & Johnson, HIV

Gilead Sciences files NDA for once-daily Truvada and TMC278 tablet for HIV

Article | 24 November 2010

Print This

Gilead Sciences (Nasdaq: GILD) yesterday submitted a New Drug Application to the US Food and Drug Administration for marketing approval ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in